Overview

Safety, Tolerability And Mechanism Of Action Of Boswellic Acids (BA) In Multiple Sclerosis (SABA)

Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
To determine the safety and tolerability of BOSWELAN in subjects with multiple sclerosis or clinically isolated syndrome and to describe the effect of Boswellic acids on the disease activity as assessed by monthly MRI measures.
Phase:
Phase 2
Details
Lead Sponsor:
Universitätsklinikum Hamburg-Eppendorf
Treatments:
Boswellic acid